Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EBITDA: 2013-2025

Historic EBITDA for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$44.3 million.

  • Coherus Oncology's EBITDA rose 5.38% to -$44.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.7 million, marking a year-over-year increase of 58.48%. This contributed to the annual value of -$111.7 million for FY2024, which is 45.05% up from last year.
  • Coherus Oncology's EBITDA amounted to -$44.3 million in Q3 2025, which was up 2.53% from -$45.5 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's EBITDA ranged from a high of $42.6 million in Q4 2024 and a low of -$167.4 million during Q1 2021.
  • Over the past 3 years, Coherus Oncology's median EBITDA value was -$45.4 million (recorded in 2025), while the average stood at -$40.9 million.
  • As far as peak fluctuations go, Coherus Oncology's EBITDA tumbled by 509.51% in 2021, and later soared by 161.83% in 2024.
  • Quarterly analysis of 5 years shows Coherus Oncology's EBITDA stood at -$39.5 million in 2021, then tumbled by 30.21% to -$51.5 million in 2022, then slumped by 33.81% to -$68.9 million in 2023, then skyrocketed by 161.83% to $42.6 million in 2024, then climbed by 5.38% to -$44.3 million in 2025.
  • Its EBITDA stands at -$44.3 million for Q3 2025, versus -$45.5 million for Q2 2025 and -$45.4 million for Q1 2025.